Skip to main content

Table 3 Summary details

From: Phase II study of olaparib in patients with refractory Ewing sarcoma following failure of standard chemotherapy

Reason treatment ended:

 

Progressive disease

N=12, 100%

Best response:

 

Stable disease

N=4, 33.33%

Progressive disease

N=8, 66.67%

Number of treatment weeks completed

 

N

12

Mean

7.9

Std

4.72

Min

4

Max

20

Duration of stable disease (weeks)

 

N

4

Mean

13.03

Std

3.28

Min

10.9

Max

17.9

Progression-free survival: median of 5.7 weeks.

 

Survival status

 

Alive

N=1, 8.33%

Dead

N=11, 91.67%